{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:16:27Z","timestamp":1795043787132,"version":"4.10.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ygyno.2021.07.016","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T17:28:17Z","timestamp":1627925297000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial"],"prefix":"10.1016","volume":"163","author":[{"given":"Nicoletta","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Lisyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.07.016_bb0005","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0010","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0015","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0020","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0025","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0030","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2021.07.016_bb0035","article-title":"Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1 [abstract]","volume":"31","author":"Banerjee","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0040","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0045","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0050","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2217\/fon-2019-0057","article-title":"Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?","volume":"15","author":"Miller","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0055","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajco.12636","article-title":"Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer","volume":"12","author":"Friedlander","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0065","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JOP.18.00705","article-title":"Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer","volume":"15","author":"Shammo","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0075","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-020-03070-0","article-title":"A real or apparent decrease in glomerular filtration rate in patients using olaparib?","volume":"77","author":"Bruin","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir. Med. J."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0095","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0105","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0110","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0115","author":"Tesaro"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0120","author":"Tesaro"},{"key":"10.1016\/j.ygyno.2021.07.016_bb0125","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-LB-273","article-title":"A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles [abstract]","volume":"78","author":"Leo","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.07.016_bb0130","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:57:46Z","timestamp":1758772666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821005783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0090825821005783"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}